MEDSCI (02415) announced that its subsidiary, Shanghai MedSci Medical Technology Co., Ltd., has recently won the bid for a major real-world research project from a Chinese pharmaceutical company. The project aims to "systematically evaluate the effectiveness and safety of IL-1β monoclonal antibody treatment for patients with acute and intermittent gout through a combination of prospective and retrospective observational studies." The contract value is approximately RMB 21 million.

The Group leverages its internet doctor platform accumulated over more than ten years of experience, applying big data and artificial intelligence technology to connect doctors, patients, and pharmaceutical and medical device companies, providing digital solutions to empower the medical ecosystem and improve medical quality.